Rare diseases
Investigational molecules
Locations
Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma
GermanyA study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations
DenmarkA study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer
BelgiumPhase 3 Study of INCB123667 versus investigator's choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression
BelgiumMaintenance Therapy Study of Inavolisib with Pertuzumab and Trastuzumab in Patients with HER2‑Positive, PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer
BelgiumStudy of ASP-1929 and pembrolizumab for patients with recurrent head and neck squamous cell carcinoma without distant metastases
PolandComparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer
BelgiumA study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy
BelgiumA study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer
CzechiaA study of mRNA-4157 and a drug combination for patients with stage IV non-small cell lung cancer
FranceEvaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma
FranceEvaluation of Raludotatug Deruxtecan With Carboplatin, Paclitaxel, or Bevacizumab in Relapsed High-grade Serous Ovarian, Peritoneal, or Fallopian Tube Cancer
SpainTell us about your condition – we search every trial in Europe and connect you with the right site.
